Re: Prostaglandin E(2) inhibition and aqueous concentration of ketorolac 0.4% and nepafenac 0.1% in patients undergoing phacoemulsification.
Walters
Tom
T
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D001082:Aqueous Humor / Q000378:metabolism*; D044482:Benzeneacetamides / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D015232:Dinoprostone / Q000037:antagonists & inhibitors*; D006801:Humans; D007124:Immunoenzyme Techniques; D020911:Ketorolac Tromethamine / Q000493:pharmacokinetics*; D018918:Phacoemulsification; D010648:Phenylacetates / Q000493:pharmacokinetics*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D044482:Benzeneacetamides; D010648:Phenylacetates; C414203:nepafenac; D020911:Ketorolac Tromethamine; D015232:Dinoprostone